Insights From ASCO 2025 Guide Pharmacy Practice in Solid Tumors and Hematologic Cancers
Pharmacy Times
JULY 16, 2025
These updated data from the CEPHEUS trial continue to support the use of dara-RVd in patients with TIE/TD NDMM while highlighting the continued need for novel therapeutic approaches for patients with high-risk MM (HRMM) observed in the trial, such as those with 2 or more HRCAs and gain/amp(1q) plus 1 or more HRCAs.
Let's personalize your content